These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

210 related articles for article (PubMed ID: 26728480)

  • 1. A randomized phase II clinical trial of personalized peptide vaccination with metronomic low-dose cyclophosphamide in patients with metastatic castration-resistant prostate cancer.
    Noguchi M; Moriya F; Koga N; Matsueda S; Sasada T; Yamada A; Kakuma T; Itoh K
    Cancer Immunol Immunother; 2016 Feb; 65(2):151-60. PubMed ID: 26728480
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Mixed 20-peptide cancer vaccine in combination with docetaxel and dexamethasone for castration-resistant prostate cancer: a randomized phase II trial.
    Noguchi M; Arai G; Egawa S; Ohyama C; Naito S; Matsumoto K; Uemura H; Nakagawa M; Nasu Y; Eto M; Suekane S; Sasada T; Shichijo S; Yamada A; Kakuma T; Itoh K
    Cancer Immunol Immunother; 2020 May; 69(5):847-857. PubMed ID: 32025848
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Immunological efficacy of herbal medicines in prostate cancer patients treated by personalized peptide vaccine.
    Koga N; Moriya F; Waki K; Yamada A; Itoh K; Noguchi M
    Cancer Sci; 2017 Dec; 108(12):2326-2332. PubMed ID: 28898532
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A randomized phase II trial of personalized peptide vaccine with low dose cyclophosphamide in biliary tract cancer.
    Shirahama T; Muroya D; Matsueda S; Yamada A; Shichijo S; Naito M; Yamashita T; Sakamoto S; Okuda K; Itoh K; Sasada T; Yutani S
    Cancer Sci; 2017 May; 108(5):838-845. PubMed ID: 28188670
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A phase II trial of personalized peptide vaccination in castration-resistant prostate cancer patients: prolongation of prostate-specific antigen doubling time.
    Noguchi M; Moriya F; Suekane S; Ohnishi R; Matsueda S; Sasada T; Yamada A; Itoh K
    BMC Cancer; 2013 Dec; 13():613. PubMed ID: 24373380
    [TBL] [Abstract][Full Text] [Related]  

  • 6. An Open-Label, Randomized Phase II Trial of Personalized Peptide Vaccination in Patients with Bladder Cancer that Progressed after Platinum-Based Chemotherapy.
    Noguchi M; Matsumoto K; Uemura H; Arai G; Eto M; Naito S; Ohyama C; Nasu Y; Tanaka M; Moriya F; Suekane S; Matsueda S; Komatsu N; Sasada T; Yamada A; Kakuma T; Itoh K
    Clin Cancer Res; 2016 Jan; 22(1):54-60. PubMed ID: 26581246
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Trial to evaluate the immunogenicity and safety of a melanoma helper peptide vaccine plus incomplete Freund's adjuvant, cyclophosphamide, and polyICLC (Mel63).
    Slingluff CL; Petroni GR; Chianese-Bullock KA; Wages NA; Olson WC; Smith KT; Haden K; Dengel LT; Dickinson A; Reed C; Gaughan EM; Grosh WW; Kaur V; Varhegyi N; Smolkin M; Galeassi NV; Deacon D; Hall EH
    J Immunother Cancer; 2021 Jan; 9(1):. PubMed ID: 33479025
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Feasibility study of personalized peptide vaccination for metastatic recurrent triple-negative breast cancer patients.
    Takahashi R; Toh U; Iwakuma N; Takenaka M; Otsuka H; Furukawa M; Fujii T; Seki N; Kawahara A; Kage M; Matsueda S; Akagi Y; Yamada A; Itoh K; Sasada T
    Breast Cancer Res; 2014 Jul; 16(4):R70. PubMed ID: 24992895
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Immunological evaluation of personalized peptide vaccination for patients with histologically unfavorable carcinoma of unknown primary site.
    Sakamoto S; Yutani S; Shichijo S; Morita M; Yamada A; Itoh K; Noguchi M
    Cancer Immunol Immunother; 2016 Oct; 65(10):1223-31. PubMed ID: 27549314
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Phase II Study of Personalized Peptide Vaccination with Both a Hepatitis C Virus-Derived Peptide and Peptides from Tumor-Associated Antigens for the Treatment of HCV-Positive Advanced Hepatocellular Carcinoma Patients.
    Yutani S; Ueshima K; Abe K; Ishiguro A; Eguchi J; Matsueda S; Komatsu N; Shichijo S; Yamada A; Itoh K; Sasada T; Kudo M; Noguchi M
    J Immunol Res; 2015; 2015():473909. PubMed ID: 26539554
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A Phase 2 Randomized Controlled Trial of Personalized Peptide Vaccine Immunotherapy with Low-dose Dexamethasone Versus Dexamethasone Alone in Chemotherapy-naive Castration-resistant Prostate Cancer.
    Yoshimura K; Minami T; Nozawa M; Kimura T; Egawa S; Fujimoto H; Yamada A; Itoh K; Uemura H
    Eur Urol; 2016 Jul; 70(1):35-41. PubMed ID: 26782346
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Phase I clinical trial of a five-peptide cancer vaccine combined with cyclophosphamide in advanced solid tumors.
    Murahashi M; Hijikata Y; Yamada K; Tanaka Y; Kishimoto J; Inoue H; Marumoto T; Takahashi A; Okazaki T; Takeda K; Hirakawa M; Fujii H; Okano S; Morita M; Baba E; Mizumoto K; Maehara Y; Tanaka M; Akashi K; Nakanishi Y; Yoshida K; Tsunoda T; Tamura K; Nakamura Y; Tani K
    Clin Immunol; 2016 May; 166-167():48-58. PubMed ID: 27072896
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Phase II study of personalized peptide vaccination for previously treated advanced colorectal cancer.
    Kibe S; Yutani S; Motoyama S; Nomura T; Tanaka N; Kawahara A; Yamaguchi T; Matsueda S; Komatsu N; Miura M; Hinai Y; Hattori S; Yamada A; Kage M; Itoh K; Akagi Y; Sasada T
    Cancer Immunol Res; 2014 Dec; 2(12):1154-62. PubMed ID: 25351849
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A randomized phase III trial of personalized peptide vaccination for castration‑resistant prostate cancer progressing after docetaxel.
    Noguchi M; Fujimoto K; Arai G; Uemura H; Hashine K; Matsumoto H; Fukasawa S; Kohjimoto Y; Nakatsu H; Takenaka A; Fujisawa M; Uemura H; Naito S; Egawa S; Fujimoto H; Hinotsu S; Itoh K
    Oncol Rep; 2021 Jan; 45(1):159-168. PubMed ID: 33200227
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A randomized phase II trial of personalized peptide vaccine plus low dose estramustine phosphate (EMP) versus standard dose EMP in patients with castration resistant prostate cancer.
    Noguchi M; Kakuma T; Uemura H; Nasu Y; Kumon H; Hirao Y; Moriya F; Suekane S; Matsuoka K; Komatsu N; Shichijo S; Yamada A; Itoh K
    Cancer Immunol Immunother; 2010 Jul; 59(7):1001-9. PubMed ID: 20146063
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A randomized phase II trial of multiepitope vaccination with melanoma peptides for cytotoxic T cells and helper T cells for patients with metastatic melanoma (E1602).
    Slingluff CL; Lee S; Zhao F; Chianese-Bullock KA; Olson WC; Butterfield LH; Whiteside TL; Leming PD; Kirkwood JM
    Clin Cancer Res; 2013 Aug; 19(15):4228-38. PubMed ID: 23653149
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Phase I trial of a cancer vaccine consisting of 20 mixed peptides in patients with castration-resistant prostate cancer: dose-related immune boosting and suppression.
    Noguchi M; Arai G; Matsumoto K; Naito S; Moriya F; Suekane S; Komatsu N; Matsueda S; Sasada T; Yamada A; Kakuma T; Itoh K
    Cancer Immunol Immunother; 2015 Apr; 64(4):493-505. PubMed ID: 25662406
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A phase I study of personalized peptide vaccination for advanced urothelial carcinoma patients who failed treatment with methotrexate, vinblastine, adriamycin and cisplatin.
    Matsumoto K; Noguchi M; Satoh T; Tabata K; Fujita T; Iwamura M; Yamada A; Komatsu N; Baba S; Itoh K
    BJU Int; 2011 Sep; 108(6):831-8. PubMed ID: 21166757
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Metronomic cyclophosphamide enhances HPV16E7 peptide vaccine induced antigen-specific and cytotoxic T-cell mediated antitumor immune response.
    Weir GM; Hrytsenko O; Stanford MM; Berinstein NL; Karkada M; Liwski RS; Mansour M
    Oncoimmunology; 2014; 3(8):e953407. PubMed ID: 25960932
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A phase I study of personalized peptide vaccination using 14 kinds of vaccine in combination with low-dose estramustine in HLA-A24-positive patients with castration-resistant prostate cancer.
    Noguchi M; Uemura H; Naito S; Akaza H; Yamada A; Itoh K
    Prostate; 2011 Apr; 71(5):470-9. PubMed ID: 20878951
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.